Medical Crossfire Rheumatology, May 2009
The patient is a 74-year-old white woman who presented with complaints o...
Osteoporotic vertebral compression fractures are a common problem and ca...
While several rheumatology products suffered from delayed approvals, Dr Gaylis explains how the rheumatology field was able to regroup in 2008 and consolidate existing knowledge. Also, he discusses the trend to incorporate more diagnostic tools into ...
Listen as Dr Gaylis lists the highlights of the current American College of Rheumatology guidelines. He stresses that these provide a very useful guide, but that they should be seen as only a guide, and not as set in stone, because no 2 patients are ...
Dr Gaylis offers his insights into the forward progress of the rheumatoid arthritis field, which points to 3 or 4 new biologics with new mechanisms of action, the evolution of diagnostic tools, and changes in clinical trial designs. He points out tha...
Here, Dr Gaylis reveals that the shift toward early biologic treatment of rheumatoid arthritis has led to improvements in patient functionality, reductions in disability claims, and increases in quality of life. He emphasizes how important it is for ...
In this video, Dr Gaylis offers his opinions on tight control in rheumatology. He speaks about the increase in the use of biologics, as well as the definition of early treatment.
Dr Gaylis briefly touches upon the variety of clinical studies that have provided evidence of the benefits of early biologic therapy, including the BeST study and switch studies.
Here, Dr Gaylis discusses the major developments in the treatment of osteoporosis, including the advent of bisphosphonates, with decreases in their dosing frequency, as well as drugs with different mechanisms of action. He also speaks about the osteo...
Listen to Dr Gaylis speak about the future availability of cathepsin K inhibitors and denosumab to treat osteoporosis.
Hear Dr Gaylis discuss how once-yearly zoledronic acid will fit into the osteoporosis treatment algorithm.
Watch this video to hear Dr Gaylis speak about teriparatide's place in the current osteoporosis treatment algorithm, as well as where he would like to see it move to in the future.
In this video, Dr Gaylis explains how biologic agents have revolutionized the treatment of ankylosing spondylitis and psoriatic arthritis, improving patients' lives dramatically.
Here, Dr Gaylis explains why rheumatologists are uniquely qualified to handle cases of fibromyalgia.
Listen as Dr Gaylis speaks to the treatment options available for managing fibromyalgia, and as he offers his views regarding opioid use for this disease.
Hear Dr Gaylis talk about how to measure success in the treatment of fibromyalgia, considering that there is no cure for it today.
Dr Gaylis discusses the need for a crossfunctional approach to treating fibromyalgia including many different kinds of support services, such as nutrition, exercise, and pscyhological counseling.
After an extensive barren period with no new choices for the treatment of gout, there are finally a few more treatments coming to the market, as described by Dr Gaylis.
While most osteoarthritis treatments aim to reduce symptoms rather than reverse or stop the disease from progressing, biologic options are beginning to enter the osteoarthritis arena, which, according to Dr Gaylis, could lead to options that will hel...
Hear Dr Gaylis discuss the latest diagnostic tools in use in rheumatology, including biomarkers, MRI, ultrasound, and radionuclear isotopes.
Watch this video to hear ideas from Dr Gaylis about future programs to be hosted on the Rheumatology Channel of MedicalCrossfire.com, including a debate about whether or not to use MRI technology to help make treatment decisions.